Science News from #ACC23
April 4–6, 2023
New Orleans, Louisiana
New Orleans, Louisiana
Top Trials from ACC 2023
Amit Khera, MD, MSc, FAHA and Joanna Chikwe, MD, FAHA, chairs of the American Heart Association Committee on Scientific Sessions Program, comment on the results of some of the top trials presented during ACC 2023.
Selected science from Saturday, March 4
CLEAR Outcomes Trial: Bempedoic Acid and Cardiovascular Outcomes in Statin Intolerant Patients at High Cardiovascular Risk
Steven E. Nissen | Cleveland Clinic, Cleveland, Ohio
TRILUMINATE Pivotal: A Landmark Randomized Clinical Trial of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation
Paul Sorajja | Santa Clara, California
Selected science from Sunday, March 5
Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations -Heart Failure (BETTER CARE-HF)
Amrita Mukhopadhyay | NYU, New York, New York
NUDGE-FLU Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake
Niklas Dyrby Johansen | Center for Translational Cardiology and Pragmatic Randomized Trials, Copenhagen University Hospital, Hellerup, Denmark
Selected science from Monday, March 6
ACCESS: A Randomized Trial Assessing The Impact Of Eliminating Copayment For High Value Preventive Medications For Low-income Seniors With Cardiovascular-related Chronic Diseases
Braden Manns, MD, MSc, University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada
Coordinating Cardiology Clinics Randomized Trial Of Interventions To Improve Outcomes (COORDINATE) -Diabetes: Primary Results
Neha J. Pagidipati | Duke Clinical Research Institute, Durham, North Carolina
